Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00483756




Registration number
NCT00483756
Ethics application status
Date submitted
6/06/2007
Date registered
7/06/2007
Date last updated
14/03/2013

Titles & IDs
Public title
Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients
Scientific title
A Phase 2 Randomized, Multicenter, Active Comparator-Controlled Trial to Evaluate the Safety and Efficacy of Co-administration of CP-690,550 and Mycophenolate Mofetil / Mycophenolate Sodium in De Novo Renal Allograft Recipients
Secondary ID [1] 0 0
A3921030
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Kidney Transplantation 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cyclosporine
Treatment: Drugs - CP-690,550
Treatment: Drugs - CP-690,550

Active comparator: 1 - Treatment Arm 1 will also receive standard of care medications

Experimental: 2 - Treatment Arm 2 will also receive standard of care medications

Experimental: 3 - Treatment Arm 3 will also receive standard of care medications


Treatment: Drugs: Cyclosporine
Standard of care

Treatment: Drugs: CP-690,550
CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12

Treatment: Drugs: CP-690,550
CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) Episode 6 Months Post-Transplant
Timepoint [1] 0 0
Baseline up to Month 6
Primary outcome [2] 0 0
Glomerular Filtration Rate (GFR) at Month 12
Timepoint [2] 0 0
2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 12
Secondary outcome [1] 0 0
Glomerular Filtration Rate (GFR) at Month 6
Timepoint [1] 0 0
2, 3, 4, and 5 hrs post iohexol intravenous bolus at Month 6
Secondary outcome [2] 0 0
Number of Participants With Progression of Chronic Allograft Lesions at Month 12
Timepoint [2] 0 0
Month 12
Secondary outcome [3] 0 0
Number of Participants With First Clinical Biopsy Proven Acute Rejection (BPAR) 12 Months Post Transplant
Timepoint [3] 0 0
Baseline up to Month 12
Secondary outcome [4] 0 0
Number of Participants With Treated Clinical Acute Rejection
Timepoint [4] 0 0
Month 6, 12
Secondary outcome [5] 0 0
Number of Participants With Combined Banff Rejection Categories (Categories 2, 3, and 4)
Timepoint [5] 0 0
Month 6, 12
Secondary outcome [6] 0 0
Number of Participants With Graft Loss
Timepoint [6] 0 0
Month 6, 12
Secondary outcome [7] 0 0
Number of Participants With Efficacy Failure
Timepoint [7] 0 0
Month 6, 12
Secondary outcome [8] 0 0
Number of Participants Who Died
Timepoint [8] 0 0
Month 6, 12
Secondary outcome [9] 0 0
Lymphocyte Subset
Timepoint [9] 0 0
Month 1, 3, 6, 12
Secondary outcome [10] 0 0
Population Pharmacokinetics (PK)
Timepoint [10] 0 0
Pre-dose-2(P-2), Pre-dose(P), 0.5,1,2 hr post-dose(PD) on Day14, Month(M) 3; P,1,2 hr PD on M1; P, 0.5, 2, 4 hr PD on M6; P-2, P, 0.5 hr PD on M9, M12 as per randomization in CP-690,550 treated; P on M3 and P, 2, 4 hr PD on M6 in CsA treated participants
Secondary outcome [11] 0 0
Glomerular Filtration Rate (GFR) by The Nankivell Equation
Timepoint [11] 0 0
Month 1, 3, 6, 9, 12
Secondary outcome [12] 0 0
Glomerular Filtration Rate (GFR) by The Cockcroft-Gault Equation
Timepoint [12] 0 0
Month 1, 3, 6, 9, 12
Secondary outcome [13] 0 0
Glomerular Filtration Rate (GFR) by The Modification of Diet in Renal Disease (MDRD) Equation
Timepoint [13] 0 0
Month 1, 3, 6, 9, 12
Secondary outcome [14] 0 0
Glomerular Filtration Rate (GFR) by The Abbreviated Modification of Diet in Renal Disease (MDRD) Equation
Timepoint [14] 0 0
Month 1, 3, 6, 9, 12
Secondary outcome [15] 0 0
Number of Participants With Clinically Significant Infections
Timepoint [15] 0 0
Baseline up to Month 12
Secondary outcome [16] 0 0
36-Item Short-Form Health Survey (SF-36)
Timepoint [16] 0 0
Baseline, Month 6, 12
Secondary outcome [17] 0 0
End-Stage Renal Disease Symptom Checklist Transplantation Module (ESRD-SCL)
Timepoint [17] 0 0
Baseline, Month 6, 12
Secondary outcome [18] 0 0
Severity of Dyspepsia Assessment (SODA)
Timepoint [18] 0 0
Baseline, Month 6, 12

Eligibility
Key inclusion criteria
* Recipient of a first-time kidney transplant
* Between the ages of 18 and 70 years, inclusive
Minimum age
18 Years
Maximum age
70 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Recipient of any non-kidney transplant

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/08/2007
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/04/2010
Sample size
Target
Accrual to date
Final
338
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Pfizer Investigational Site - Camperdown
Recruitment hospital [2] 0 0
Pfizer Investigational Site - Westmead
Recruitment hospital [3] 0 0
Pfizer Investigational Site - Adelaide
Recruitment hospital [4] 0 0
Pfizer Investigational Site - Woodville
Recruitment hospital [5] 0 0
Pfizer Investigational Site - Clayton
Recruitment hospital [6] 0 0
Pfizer Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
2050 - Camperdown
Recruitment postcode(s) [2] 0 0
2145 - Westmead
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
5011 - Woodville
Recruitment postcode(s) [5] 0 0
3168 - Clayton
Recruitment postcode(s) [6] 0 0
3050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arkansas
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Maryland
Country [8] 0 0
United States of America
State/province [8] 0 0
Massachusetts
Country [9] 0 0
United States of America
State/province [9] 0 0
Michigan
Country [10] 0 0
United States of America
State/province [10] 0 0
Minnesota
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
South Carolina
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
Belgium
State/province [19] 0 0
Anderlecht
Country [20] 0 0
Belgium
State/province [20] 0 0
Leuven
Country [21] 0 0
Brazil
State/province [21] 0 0
RS
Country [22] 0 0
Brazil
State/province [22] 0 0
SP
Country [23] 0 0
Canada
State/province [23] 0 0
Alberta
Country [24] 0 0
Czech Republic
State/province [24] 0 0
Praha 4
Country [25] 0 0
France
State/province [25] 0 0
Nantes
Country [26] 0 0
France
State/province [26] 0 0
Paris Cedex 15
Country [27] 0 0
France
State/province [27] 0 0
Toulouse Cedex 9
Country [28] 0 0
France
State/province [28] 0 0
Vandoeuvre Les Nancy
Country [29] 0 0
Germany
State/province [29] 0 0
Berlin
Country [30] 0 0
Germany
State/province [30] 0 0
Hamburg
Country [31] 0 0
Italy
State/province [31] 0 0
Bologna
Country [32] 0 0
Italy
State/province [32] 0 0
Roma
Country [33] 0 0
Korea, Republic of
State/province [33] 0 0
Seoul
Country [34] 0 0
Netherlands
State/province [34] 0 0
Rotterdam
Country [35] 0 0
Norway
State/province [35] 0 0
Oslo
Country [36] 0 0
Poland
State/province [36] 0 0
Warszawa
Country [37] 0 0
Poland
State/province [37] 0 0
Wroclaw
Country [38] 0 0
Portugal
State/province [38] 0 0
Coimbra
Country [39] 0 0
Portugal
State/province [39] 0 0
Lisboa
Country [40] 0 0
Spain
State/province [40] 0 0
Barcelona

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Pfizer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Pfizer CT.gov Call Center
Address 0 0
Pfizer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00483756